Arthritis and Rheumatism

    Title / AuthorCited byYear
    Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part II
    RC Lawrence, DT Felson, CG Helmick, LM Arnold, H Choi, RA Deyo, ...
    Arthritis & Rheumatism 58 (1), 26-35
    American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease‐modifying antirheumatic drugs in rheumatoid arthritis
    KG Saag, GG Teng, NM Patkar, J Anuntiyo, C Finney, JR Curtis, ...
    Arthritis Care & Research 59 (6), 762-784
    Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: Part I
    CG Helmick, DT Felson, RC Lawrence, S Gabriel, R Hirsch, CK Kwoh, ...
    Arthritis & Rheumatism 58 (1), 15-25
    2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative
    D Aletaha, T Neogi, AJ Silman, J Funovits, DT Felson, CO Bingham III, ...
    Arthritis & Rheumatism 62 (9), 2569-2581
    Interleukin‐6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease‐modifying antirheumatic drugs: The tocilizumab in combination with traditional disease‐modifying antirheumatic drug therapy study
    MC Genovese, JD McKay, EL Nasonov, EF Mysler, NA da Silva, ...
    Arthritis & Rheumatism 58 (10), 2968-2980
    Distinct regulation of interleukin‐17 in human T helper lymphocytes
    Z Chen, CM Tato, L Muul, A Laurence, JJ O'Shea
    Arthritis & Rheumatism 56 (9), 2936-2946
    Altered expression of MicroRNA in synovial fibroblasts and synovial tissue in rheumatoid arthritis
    J Stanczyk, DML Pedrioli, F Brentano, O Sanchez‐Pernaute, C Kolling, ...
    Arthritis & Rheumatism 58 (4), 1001-1009
    Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis
    JHW Distler, A Jüngel, LC Huber, U Schulze‐Horsel, J Zwerina, RE Gay, ...
    Arthritis & Rheumatism 56 (1), 311-322
    Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study
    F Wolfe, K Michaud
    Arthritis & Rheumatism 56 (9), 2886-2895
    Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty‐two–week, phase III, multicenter, randomized, double‐blind, placebo‐controlled, parallel‐group study
    E Keystone, DVD Heijde, D Mason Jr, R Landewé, RV Vollenhoven, ...
    Arthritis & Rheumatism 58 (11), 3319-3329
    Gabapentin in the treatment of fibromyalgia: A randomized, double‐blind, placebo‐controlled, multicenter trial
    LM Arnold, DL Goldenberg, SB Stanford, JK Lalonde, HS Sandhu, ...
    Arthritis & Rheumatism 56 (4), 1336-1344
    Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen‐induced arthritis
    A Augello, R Tasso, SM Negrini, R Cancedda, G Pennesi
    Arthritis & Rheumatism 56 (4), 1175-1186
    Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection
    JJ Gómez‐Reino, L Carmona, M Ángel Descalzo
    Arthritis Care & Research 57 (5), 756-761
    Expression of microRNA‐146 in rheumatoid arthritis synovial tissue
    T Nakasa, S Miyaki, A Okubo, M Hashimoto, K Nishida, M Ochi, ...
    Arthritis & Rheumatism 58 (5), 1284-1292
    Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: A double‐blind, randomized, placebo‐controlled trial
    H van Dongen, J van Aken, LR Lard, K Visser, HK Ronday, ...
    Arthritis & Rheumatism 56 (5), 1424-1432
    Outcomes after switching from one anti–tumor necrosis factor α agent to a second anti–tumor necrosis factor α agent in patients with rheumatoid arthritis: Results from a large UK national cohort study
    KL Hyrich, M Lunt, KD Watson, DPM Symmons, AJ Silman
    Arthritis & Rheumatism 56 (1), 13-20
    A prediction rule for disease outcome in patients with Recent‐onset undifferentiated arthritis: How to guide individual treatment decisions
    AHM van der Helm‐vanMil, S le Cessie, H van Dongen, FC Breedveld, ...
    Arthritis & Rheumatism 56 (2), 433-440
    Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: A twelve‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II clinical trial
    SB Cohen, RK Dore, NE Lane, PA Ory, CG Peterfy, JT Sharp, ...
    Arthritis & Rheumatism 58 (5), 1299-1309
    Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti–tumor necrosis factor α therapy: Results from the British Society for Rheumatology Biologics Register
    WG Dixon, KD Watson, M Lunt, KL Hyrich, AJ Silman, DPM Symmons
    Arthritis & Rheumatism 56 (9), 2905-2912
    Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: An open‐label extension analysis
    E Keystone, R Fleischmann, P Emery, DE Furst, R van Vollenhoven, ...
    Arthritis & Rheumatism 56 (12), 3896-3908
    1 - 20